Twenty-year survivors of heart transplantation at Stanford University

被引:37
作者
Deuse, T. [1 ]
Haddad, F. [2 ]
Pham, M. [2 ]
Hunt, S. [2 ]
Valantine, H. [2 ]
Bates, M. J. [1 ]
Mallidi, H. R. [1 ]
Oyer, P. E. [1 ]
Robbins, R. C. [1 ]
Reitz, B. A. [1 ]
机构
[1] Stanford Univ, Sch Med, Dept Cardiothorac Surg, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Dept Cardiothorac Med, Stanford, CA 94305 USA
关键词
heart transplantation; long-term graft survival; morbidity;
D O I
10.1111/j.1600-6143.2008.02310.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Human heart transplantation started 40 years ago. Medical records of all cardiac transplants performed at Stanford were reviewed. A total of 1446 heart transplantations have been performed between January 1968 and December 2007 with an increase of 1-year survival from 43.1% to 90.2%. Sixty patients who were transplanted between 1968 and 1987 were identified who survived at least 20 years. Twenty-year survivors had a mean age at transplant of 29.4 +/- 13.6 years. Rejection-free and infection-free 1-year survivals were 14.3% and 18.8%, respectively. At their last follow-up, 86.7% of long-term survivors were treated for hypertension, 28.3% showed chronic renal dysfunction, 6.7% required hemodialysis, 10% were status postkidney transplantation, 13.3% were treated for diabetes mellitus, 36.7% had a history of malignancy and 43.3% had evidence of allograft vasculopathy. The half-life conditional on survival to 20 years was 28.1 years. Eleven patients received a second heart transplant after 11.9 +/- 8.0 years. The most common causes of death were allograft vasculopathy (56.3%) and nonlymphoid malignancy (25.0%). Twenty-year survival was achieved in 12.5% of patients transplanted before 1988. Although still associated with considerable morbidity, long-term survival is expected to occur at much higher rates in the future due to major advances in the field over the past decade.
引用
收藏
页码:1769 / 1774
页数:6
相关论文
共 29 条
[1]  
BAUM D, 1991, PEDIATRICS, V88, P203
[2]   USE OF RABBIT ANTITHYMOCYTE GLOBULIN IN CARDIAC TRANSPLANTATION - RELATIONSHIP OF SERUM CLEARANCE RATES TO CLINICAL OUTCOME [J].
BIEBER, CP ;
GRIEPP, RB ;
OYER, PE ;
WONG, J ;
STINSON, EB .
TRANSPLANTATION, 1976, 22 (05) :478-488
[3]   Registry of the International Society for Heart and Lung Transplantation: Tenth official pediatric heart transplantation report - 2007 [J].
Boucek, Mark M. ;
Aurora, Paul ;
Edwards, Leah B. ;
Taylor, David O. ;
Trulock, Elbert P. ;
Christie, Jason ;
Dobbels, Fabienne ;
Rahmel, Axel O. ;
Keck, Berkeley M. ;
Hertz, Marshall I. .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2007, 26 (08) :796-807
[4]   PERCUTANEOUS TRANSVENOUS ENDOMYOCARDIAL BIOPSY [J].
CAVES, PK ;
STINSON, EB ;
GRAHAM, AF ;
BILLINGHAM, ME ;
GREHL, TM ;
SHUMWAY, NE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1973, 225 (03) :288-291
[5]   CYTOMEGALO-VIRUS INFECTION IS ASSOCIATED WITH CARDIAC ALLOGRAFT-REJECTION AND ATHEROSCLEROSIS [J].
GRATTAN, MT ;
MORENOCABRAL, CE ;
STARNES, VA ;
OYER, PE ;
STINSON, EB ;
SHUMWAY, NE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 261 (24) :3561-3566
[6]  
GRIEPP RB, 1970, CALIF MED, V113, P17
[7]   HUMAN HEART-TRANSPLANTATION - CURRENT STATUS [J].
GRIEPP, RB ;
STINSON, EB ;
BIEBER, CP ;
REITZ, BA ;
COPELAND, JG ;
OYER, PE ;
SHUMWAY, NE .
ANNALS OF THORACIC SURGERY, 1976, 22 (02) :171-175
[8]   Incidence of cancer after immunosuppressive treatment for heart transplantation [J].
Ippoliti, G ;
Rinaldi, M ;
Pellegrini, C ;
Viganò, M .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 56 (01) :101-113
[9]   Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease [J].
Kato, T ;
Tokoro, T ;
Namii, Y ;
Kobayashi, T ;
Hayashi, S ;
Yokoyama, I ;
Morimoto, S ;
Chan, M ;
Giannetti, N ;
Hunt, SA .
TRANSPLANTATION PROCEEDINGS, 2000, 32 (02) :331-333
[10]   Calcineurin inhibitors in heart transplantation [J].
Keogh, A .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2004, 23 (05) :S202-S206